#Canada #Toronto #Biopharma #Xtalks #Hybrid Modeling

Webinar Overview

As the biopharmaceutical landscape becomes increasingly competitive, the need for faster and more efficient processes is paramount. A webinar hosted by Xtalks aims to address this issue by introducing hybrid modeling as a revolutionary approach in upstream process development. Scheduled for November 17, 2026, at 11 AM EST, this session will outline how hybrid modeling can significantly speed up the optimization of product-quality attributes through predictive decision-making.

The Challenges in Upstream Development

In biopharmaceutical development, upstream processes are often constrained by tight deadlines. Teams must deliver quality-targeted processes rapidly, relying heavily on both prior knowledge and the expert judgment of scientists. Unfortunately, historical bioreactor data is infrequently used quantitatively, which can hinder development timelines and lead to inefficiencies in the decision-making process.

Unleashing the Power of Hybrid Modeling

Hybrid modeling stands out as a game-changer in biopharmaceutical development, allowing teams to incorporate predictive decision-making much earlier in the process. This technique offers a data-driven approach, reusing information from previous projects to develop reliable models, even when new experimental data is yet to be generated.

The webinar features notable experts from Bristol Myers Squibb, Juan C. Gonzalez Rivera, PhD, and Yikun Huang, PhD, who will demonstrate through practical case studies how this hybrid approach can overcome existing challenges. The discussion will delve into how to effectively use multivariate strategies to identify relevant historical programs. By comparing product quality and process performance, these strategies enable teams to create models that ensure products meet the necessary quality before moving on to the next stage.

Case Studies Demonstrating Efficiency

Participants will explore two insightful case studies illustrating the successful application of model-based approaches. The first examines a monoclonal antibody intermediate for an antibody-drug conjugate (ADC), where model-guided optimization played a crucial role in reducing the presence of acidic variants without needing additional experiments. The second case focuses on another ADC intermediate undergoing first-in-human development, applying similar techniques to improve glycan quality attributes.

These real-world examples highlight how hybrid modeling aids in controlling multiple product-quality attributes earlier in development phases, effectively shortening overall timelines and reducing the number of experimental runs by as much as 50% compared to traditional workflows.

The Benefits of Attending

With insights into integrating historical data, hybrid models, and molecule-specific experimentation, attendees will learn how to transition from sequential, intuition-driven optimization to a more streamlined, model-based decision-making process. This strategic shift can cut development timelines down by as much as six months, leading to the more efficient use of resources and improved product outcomes.

To wrap up, the webinar will empower professionals by providing essential knowledge for implementing hybrid modeling effectively in their processes. This new approach promises not only to enhance productivity but also to maintain the integrity and quality of biopharmaceutical products.

Register Now!

To learn more about how hybrid modeling can revolutionize your pharmaceutical development processes, register for this essential webinar at the Xtalks website. Don't miss out on the opportunity to gain valuable insights from the industry’s leading experts and position your organization for success in the biopharmaceutical sector.

Learn more at Xtalks.